Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Estrogen Metabolites in CRC

Are they associated with risk?

Publish date:: June 30, 2015

Circulating estrogens and their metabolites were generally unrelated to CRC risk in postmenopausal women, according to a study of 15,595 women who donated blood. Researchers measured estrogen metabolites (EMs) in 187 women with colorectal cancer (CRC) and in 501 women not using exogenous hormones. Researchers found:

• No significant associations were found for estrone, estradiol, or total EMs.

• Most metabolites in the 2-, 4-, or 16-pathway were unrelated to risk; a borderline risk was associated with high levels of 17-epiestriol.

Citation: Falk RT, Dallal CM, Lacey JV Jr, et al. Estrogen Metabolites Are Not Associated With Colorectal Cancer Risk In Postmenopausal Women. [Published online ahead of print June 23, 2015]. Cancer Epidemiol Biomarkers Prev. doi: 10.1158/1055-9965.EPI-15-0541.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,